
Appendix C

Monthly Part D Spending on Hepatitis C Drugs Since 2014

Month	Non-Gilead HCV Drugs	SOVALDI	HARVONI	Grand Total
Jan-14	\$28,442,376	\$87,971,156		\$116,413,532
Feb-14	\$43,853,177	\$172,286,950		\$216,140,127
Mar-14	\$76,366,244	\$279,584,516		\$355,950,760
Apr-14	\$100,038,835	\$335,657,011		\$435,695,845
May-14	\$117,118,858	\$374,015,256		\$491,134,114
Jun-14	\$119,223,080	\$362,401,672		\$481,624,753
Jul-14	\$123,297,596	\$357,824,949		\$481,122,544
Aug-14	\$109,346,905	\$307,513,498		\$416,860,404
Sep-14	\$98,500,726	\$274,536,702		\$373,037,428
Oct-14	\$84,139,502	\$243,317,636	\$52,627,766	\$380,084,904
Nov-14	\$50,040,416	\$160,278,599	\$211,035,968	\$421,354,984
Dec-14	\$41,520,872	\$151,573,035	\$436,228,838	\$629,322,745
Jan-15	\$31,306,240	\$111,180,236	\$484,972,311	\$627,458,787
Feb-15	\$33,999,630	\$108,632,947	\$552,282,193	\$694,914,770
Mar-15	\$39,714,722	\$121,356,036	\$702,916,231	\$863,986,988
Apr-15	\$36,506,518	\$114,514,855	\$686,400,733	\$837,422,106
May-15	\$31,753,078	\$104,467,097	\$636,896,854	\$773,117,030
Jun-15	\$30,554,998	\$109,482,553	\$653,142,640	\$793,180,191
Grand Total	\$1,195,723,772	\$3,776,594,704	\$4,416,503,535	\$9,388,822,010

Source: CMS Chronic Conditions Warehouse, <http://ccwdata.org>.
 Note: Spending data are prior to rebates.

CY2013 Part D Spending on HCV Drugs

Drug Name	Spending
INCIVEK	\$177,000,000
INTERFERON	\$138,000,000
VICTRELIS	\$45,000,000
RIBAVIRIN	\$18,000,000
SOVALDI	\$14,000,000
OLYSIO	\$2,000,000
Grand Total	\$394,000,000

Source: Centers for Medicare & Medicaid Services, Office of Enterprise Data and Analytics.

Notes: Spending data are prior to rebates; Olysio was approved by the FDA on November 22, 2013; Sovaldi was approved by the FDA on December 6, 2013.

CY2014 Part D Spending on HCV Drugs

Drug Name	Spending
SOVALDI	\$3,106,960,981
OLYSIO	\$833,253,319
HARVONI	\$699,892,572
Other	\$158,635,267
Grand Total	\$4,798,742,139

Source: CMS Chronic Conditions Warehouse, <http://ccwdata.org>.


Notes: Spending data are prior to rebates; Harvoni was approved by the FDA on October 10, 2014; "Other" includes Copegus, Pegasys, Pegasys Proclick, Moderiba, Intron-A w Diluent, Victrelis, Intron-A, Rebetol, Rebetron, Peg-Intron, Sylatron, Peg-Intron Redipen, Ribavirin, Virazole, Infergen, Ribatab, Ribapak, Ribasphere, Incivek, Ribasphere, and Ribapak.

CY2015 Part D HCV Spending (Through June 30)


Drug Name	Spending
HARVONI	\$3,716,610,962
SOVALDI	\$669,633,723
VIEKIRA PAK	\$93,767,208
OLYSIO	\$88,907,976
Other	\$21,160,002
Grand Total	\$4,590,079,872

Source: CMS Chronic Conditions Warehouse, <http://ccwdata.org>.

Notes: Spending data are prior to rebates; "Other" includes Copegus, Pegasys, Pegasys Proclick, Moderiba, Intron-A w Diluent, Victrelis, Intron-A, Rebetol, Rebetron, Peg-Intron, Sylatron, Peg-Intron Redipen, Ribavirin, Virazole, Infergen, Ribatab, Ribapak, Ribasphere, Incivek, Ribasphere, and Ribapak.



Source: CMS Chronic Conditions Warehouse, <http://ccwdata.org/index.php>
 Notes: Spending data are prior to rebates; Harvoni was approved by the FDA on October 10, 2014; "Other" includes Copegus, Pegsaps, Pegsaps Proclck, Modertiba, Intron-A w Diluent, Victrelis, Intron-A, Rebetol, Rebetron, Peg-Intron, Sylatron, Virazole, Infigen, Ribataab, Ribapak, RibaspHERE, Inctevk, RibaspHERE, and Ribapak.



Source: CMS Chronic Conditions Warehouse, <http://ccwdata.org/index.php>.
 Notes: Spending data are prior to rebates; "Other" includes Coppegas, Pegasis, Pegasis Proclack, Moderiba, Intron-A w Diluent, Victrelis, Intron-A, Rebetol, Rebetron, Peg-Intron, Silyatron, Peg-Intron Redipen, Ribavirin, Virazole, Infigen, Ribatab, Ribapak, Ribasphere, Incivek, Ribasphere, and Ribapak.

